LEAP-007
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)
- NCT03829332 ↗
- Completed
- Merck Sharp & Dohme LLC
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on LEAP-007 (lenvatinib plus pembrolizumab in PD-L1-positive treatment-naïve metastatic non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LEAP-007 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 6 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Nonsmall Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Pembrolizumab; Lenvatinib; Placebo for lenvatinib
- Arms
- Pembrolizumab + Lenvatinib · Experimental
- Pembrolizumab + Placebo · Active comparator
- Enrollment
- 623
- Primary outcomes
- Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC with Eisai Inc.
- Start
- Mar 13, 2019
- Primary completion
- May 19, 2021
- Results posted
- Yes
- Registry record
- NCT03829332 · updated Feb 19, 2026
Publications
linked from the registry- Yang JC, Han B, De La Mora Jimenez E, Lee JS, Koralewski P, Karadurmus N, Sugawara S, Livi L, Basappa NS, Quantin X, Dudnik J, Ortiz DM, Mekhail T, Okpara CE, Dutcus C, Zimmer Z, Samkari A, Bhagwati N, Csoszi T. Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial. J Thorac Oncol. 2024 Jun;19(6):941-953. doi: 10.1016/j.jtho.2023.12.023. Epub 2023 Dec 29. PubMed 38159809
- Taylor MH, Schmidt EV, Dutcus C, Pinheiro EM, Funahashi Y, Lubiniecki G, Rasco D. The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncol. 2021 Feb;17(6):637-648. doi: 10.2217/fon-2020-0937. Epub 2020 Dec 10. PubMed 33300372